ALK208 / Allink Biotherapeutics - LARVOL DELTA

A first-in-class PD-L1/B7-H3/VEGF tri-specific ADC achieves enhanced preclinical antitumor efficacy through direct cytotoxicity, immune checkpoint blockade and VEGF inhibition (AACR 2026) - "In xenograft models, ALK208 outperformed clinical-stage PD-L1 and PD-L1/B7-H3 ADCs. In summary, ALK208 is a first-in-class PD-L1/B7-H3/VEGF trispecific ADC that integrates multiple complementary mechanisms to maximize antitumor efficacy while maintaining a promising safety profile."

ADC • Checkpoint block • Checkpoint inhibition • Preclinical • Trispecific • Oncology • Solid Tumor • CD276 • PD-L1